Hansoh Pharma is becoming an emerging leader in metabolic diseases, and we see Mercks expertise and capabilities as key to accelerating the development of this promising asset for patients worldwide.
Store in a cool, dry place, out of reach of children
Another mechanism of action of BPC-157 is blocking the inhibitory growth factor called 4-hydroxynonenal, which is a negative modulator of growth
These effects are particularly relevant in the context of obesity and metabolic syndrome, as noted in studies involving high-fat diet models that demonstrated a significant reduction in liver fat in EGCG-treated groups
Zhang J, Lv S, Peng X, Liu H, Guo J, Liu Z, et al
Knowledge is power, and we want you to leave feeling informed about your health decisions